FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892632954> ?p ?o ?g. }

• W2892632954 endingPage "93" @default.
• W2892632954 startingPage "80" @default.
• W2892632954 abstract "Observational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM-α), pemafibrate, will be used to target residual cardiovascular risk remaining after treatment to reduce low-density lipoprotein cholesterol (LDL-C) in individuals with the dyslipidemia of type 2 diabetes mellitus (T2). The PROMINENT study will randomly allocate approximately 10,000 participants with T2D, mild-to-moderate hypertriglyceridemia (TG: 200-499 mg/dl; 2.26-5.64 mmol/l) and low high-density lipoprotein cholesterol levels (HDL-C: ≤40 mg/dl; 1.03 mmol/l) to either pemafibrate (0.2 mg twice daily) or matching placebo with an average expected follow-up period of 3.75 years (total treatment phase 5 years; 24 countries). At study entry, participants must be receiving either moderate-to-high intensity statin therapy or meet specified LDL-C criteria. The study population will be one-third primary and two-thirds secondary prevention (established cardiovascular disease). The primary endpoint is a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for unstable angina requiring urgent coronary revascularization, and cardiovascular death. This event-driven study will complete when 1092 adjudicated primary endpoints have accrued with at least 200 occurring in women. Statistical power is at least 90% to detect an 18% reduction in the primary endpoint. Pre-specified secondary and tertiary endpoints include all-cause mortality, hospitalization for heart failure, new or worsening peripheral artery disease, new or worsening diabetic retinopathy and nephropathy, and change in biomarkers including select lipid and non-lipid biomarkers, inflammatory and glycemic parameters." @default.
• W2892632954 created "2018-10-05" @default.
• W2892632954 creator A5003186890 @default.
• W2892632954 creator A5007048045 @default.
• W2892632954 creator A5023091399 @default.
• W2892632954 creator A5025632184 @default.
• W2892632954 creator A5028480812 @default.
• W2892632954 creator A5035876498 @default.
• W2892632954 creator A5036558176 @default.
• W2892632954 creator A5037322697 @default.
• W2892632954 creator A5043201732 @default.
• W2892632954 creator A5045857025 @default.
• W2892632954 creator A5058350680 @default.
• W2892632954 creator A5076746946 @default.
• W2892632954 creator A5079728437 @default.
• W2892632954 creator A5091595592 @default.
• W2892632954 date "2018-12-01" @default.
• W2892632954 modified "2023-10-05" @default.
• W2892632954 title "Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study" @default.
• W2892632954 cites W1489291293 @default.
• W2892632954 cites W1604940037 @default.
• W2892632954 cites W161660362 @default.
• W2892632954 cites W1672804368 @default.
• W2892632954 cites W1966788643 @default.
• W2892632954 cites W1968541049 @default.
• W2892632954 cites W1969927159 @default.
• W2892632954 cites W1972538440 @default.
• W2892632954 cites W1974139741 @default.
• W2892632954 cites W1975018096 @default.
• W2892632954 cites W1975936284 @default.
• W2892632954 cites W1987751736 @default.
• W2892632954 cites W1994789322 @default.
• W2892632954 cites W2020659754 @default.
• W2892632954 cites W2020915011 @default.
• W2892632954 cites W2022162088 @default.
• W2892632954 cites W2028145176 @default.
• W2892632954 cites W2040770080 @default.
• W2892632954 cites W2041380076 @default.
• W2892632954 cites W2048760408 @default.
• W2892632954 cites W2050838276 @default.
• W2892632954 cites W2052644460 @default.
• W2892632954 cites W2052781017 @default.
• W2892632954 cites W2054851194 @default.
• W2892632954 cites W2061100095 @default.
• W2892632954 cites W2071298734 @default.
• W2892632954 cites W2083454724 @default.
• W2892632954 cites W2089035720 @default.
• W2892632954 cites W2097893773 @default.
• W2892632954 cites W2103393658 @default.
• W2892632954 cites W2104720567 @default.
• W2892632954 cites W2107665972 @default.
• W2892632954 cites W2108169164 @default.
• W2892632954 cites W2111099202 @default.
• W2892632954 cites W2112848098 @default.
• W2892632954 cites W2114056762 @default.
• W2892632954 cites W2115801316 @default.
• W2892632954 cites W2117092539 @default.
• W2892632954 cites W2118825330 @default.
• W2892632954 cites W2127427274 @default.
• W2892632954 cites W2139362648 @default.
• W2892632954 cites W2143716053 @default.
• W2892632954 cites W2144516660 @default.
• W2892632954 cites W2145813488 @default.
• W2892632954 cites W2150100875 @default.
• W2892632954 cites W2153118028 @default.
• W2892632954 cites W2156696514 @default.
• W2892632954 cites W2159738130 @default.
• W2892632954 cites W2163096122 @default.
• W2892632954 cites W2163969089 @default.
• W2892632954 cites W2164324917 @default.
• W2892632954 cites W2165605025 @default.
• W2892632954 cites W2170009139 @default.
• W2892632954 cites W2198678228 @default.
• W2892632954 cites W2216998043 @default.
• W2892632954 cites W2280192011 @default.
• W2892632954 cites W2286634515 @default.
• W2892632954 cites W2289823333 @default.
• W2892632954 cites W2291598045 @default.
• W2892632954 cites W2294822677 @default.
• W2892632954 cites W2323589075 @default.
• W2892632954 cites W2328529137 @default.
• W2892632954 cites W2341439667 @default.
• W2892632954 cites W2341665659 @default.
• W2892632954 cites W2400712338 @default.
• W2892632954 cites W2475856355 @default.
• W2892632954 cites W2519479884 @default.
• W2892632954 cites W2595721094 @default.
• W2892632954 cites W2599479486 @default.
• W2892632954 cites W2616536890 @default.
• W2892632954 cites W2617842398 @default.
• W2892632954 cites W2748400555 @default.
• W2892632954 cites W2762341782 @default.
• W2892632954 cites W2762777606 @default.
• W2892632954 cites W2765263832 @default.
• W2892632954 cites W2765954021 @default.
• W2892632954 cites W2767128978 @default.
• W2892632954 cites W2782064714 @default.
• W2892632954 cites W2791151548 @default.

• next